|
|
|
|
|
24.06.25 - 14:06
|
CommScope′s Mittal Parekh Elected to Wireless Broadband Alliance Board of Directors (Business Wire)
|
|
|
Senior Director for CommScope's RUCKUS Networks business brings wireless network experience, insights to new roleCLAREMONT, N.C.--(BUSINESS WIRE)--#RUCKUSNetworks--CommScope (NASDAQ: COMM), a global leader in network connectivity, announced today that Mittal Parekh, Senior Director, Products for RUCKUS Networks, CommScope, has been elected to the Board of Directors of the Wireless Broadband Alliance (WBA) for a four-year term, effective July 1, 2025. RUCKUS has been an active WBA member since 2010 (through CommScope since 2018) and has been recognized for active participation in WBA's governance and development efforts, as well as being a founding member of WBA's Enterprise Connectivity Forum.
WBA is a global organization that connects people with the latest wireless initiatives by advancing advocacy, industry guidelines, trials and certification through collaboration across a range of connectivity-focused industries. As a member of the board, Parekh will work with other wireless industry leaders from ...
|
|
|
|
|
|
|
|
|
|
|
23.06.25 - 16:57
|
ArcelorMittal Buy (DPA-AFX)
|
|
|
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für ArcelorMittal nach dem Besuch eines Stahlwerks im spanischen Bilbao auf "Buy" mit einem Kursziel von 33,30 Euro belassen. Der Standort sei bekannt für den Großteil der CO2-armen ......
|
|
|
|
|
|
|
23.06.25 - 14:06
|
Redfin Reports Home Prices Grow at Slowest Pace in Nearly Two Years (Business Wire)
|
|
|
It took 38 days for the typical home to go under contract—the slowest May pace since 2020—and sales were canceled at the highest May rate on recordSEATTLE--(BUSINESS WIRE)--#housingmarket--(NASDAQ: RDFN) —The median U.S. home-sale price rose 0.7% year over year in May—the slowest growth since June 2023. That's according to a new report from Redfin (redfin.com), the technology-powered real estate brokerage. Still, last month's median sale price of $440,997 was the highest of any May in records dating back to 2012.
Redfin recently predicted that home prices will start falling on a year-over-year basis by the end of 2025. That has already happened in 11 of the 50 most populous U.S. metropolitan areas, with Oakland, CA (-6.7%), Jacksonville, FL (-5.2%) and Dallas (-4.6%) leading the declines in May.
Home Price Growth Is Cooling Because Sellers Outnumber Buyers
U.S. home price growth is slowing because there are significantly more home sellers than buyers in today's market—the result of prohibitiv...
|
|
|
|
|
|
|
|
|
23.06.25 - 10:03
|
European Medicines Agency Recommends Market Approval of AVT06, Alvotech′s Proposed Biosimilar to Eylea® (aflibercept) (GlobeNewswire EN)
|
|
|
REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein....
|
|
|
23.06.25 - 10:03
|
European Medicines Agency Recommends Market Approval of AVT06, Alvotech′s Proposed Biosimilar to Eylea® (aflibercept) (GlobeNewswire EN)
|
|
|
REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein....
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
